Anixa Biosciences Inc
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
- Ticker
- ANIX
- Trading on
- NASDAQ
- ISIN
- -
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Dr. Amit Kumar Ph.D.
- Headquarters
- 3150 Almaden Expressway, San Jose, CA, United States, 95118
- Employees
- 4
- Website
- anixa.com
Metrics
Analyst Insights & forecasts
Based on information from 3 analysts.
Earnings per share (EPS) forecast
| Q4 • 25 | Q1 • 26 | Q2 • 26 | |
|---|---|---|---|
| Actual | -$0.08 | -$0.08 | -$0.07 |
| Expected | -$0.08 | -$0.09 | -$0.10 |
| Surprise | 3.96% | 11.11% | 30.00% |
| Beat | Beat | Current |
Financial Performance
| Q2 • 26 | Q3 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $0M | $0M | NaN% |
| Net income | $-2.6M | $-2.6M | 1.96% |
| Profit margin | -∞% | -∞% | NaN% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a Anixa Biosciences Inc share?
Anixa Biosciences Inc shares are currently traded for undefined per share.
02How many shares does Anixa Biosciences Inc have?
Anixa Biosciences Inc currently has 34.8M shares.
03Does Anixa Biosciences Inc pay dividends?
No, Anixa Biosciences Inc doesn't pay dividends.
04What is Anixa Biosciences Inc 52 week high?
Anixa Biosciences Inc 52 week high is $5.46.
05What is Anixa Biosciences Inc 52 week low?
Anixa Biosciences Inc 52 week low is $2.32.
06What is the 200-day moving average of Anixa Biosciences Inc?
Anixa Biosciences Inc 200-day moving average is $2.96.
07Who is Anixa Biosciences Inc CEO?
The CEO of Anixa Biosciences Inc is Dr. Amit Kumar Ph.D..
08How many employees Anixa Biosciences Inc has?
Anixa Biosciences Inc has 4 employees.
09What is the market cap of Anixa Biosciences Inc?
The market cap of Anixa Biosciences Inc is $91.1M.
10What is the P/E of Anixa Biosciences Inc?
The current P/E of Anixa Biosciences Inc is null.
11What is the EPS of Anixa Biosciences Inc?
The EPS of Anixa Biosciences Inc is -$0.32.
12What is the PEG Ratio of Anixa Biosciences Inc?
The PEG Ratio of Anixa Biosciences Inc is null.
13What do analysts say about Anixa Biosciences Inc?
According to the analysts Anixa Biosciences Inc is considered a buy.


